一项前瞻性多中心双盲随机对照试验:重复经颅磁刺激增强电休克治疗对难治性抑郁症患者临床、认知与神经效应的评估(STIMAGNECT 2)
STIMAGNECT 2是一项前瞻性多中心双盲随机对照试验,计划纳入80例难治性抑郁症患者,全部接受10次电休克治疗,随机分配至活性或假重复经颅磁刺激组。主要结局为10次电休克治疗后的应答率,即汉密尔顿抑郁量表(21项)评分较基线降低≥50%的患者比例。
要点
- 80例难治性抑郁症患者将随机接受活性或假重复经颅磁刺激联合10次电休克治疗。
- 主要结局为10次电休克治疗后汉密尔顿抑郁量表(21项)评分降低≥50%的应答率。
- 次要结局包括抑郁严重度、副作用、认知功能、自传体记忆及电休克参数和MRI指标。
核心结论
- 该试验旨在利用重复经颅磁刺激与电休克的协同效应优化神经刺激方案,以改善难治性抑郁症的治疗。
研究设计与样本
- 前瞻性多中心双盲随机对照试验,计划纳入80例难治性抑郁症患者,全部接受10次电休克治疗,随机分配至活性或假重复经颅磁刺激组。
- 重复经颅磁刺激方案为电休克开始前4天内进行5次刺激,自第6次电休克起每次电休克前一天额外进行1次刺激。
关键数值与推荐
- 主要结局为10次电休克治疗后的应答率,定义为汉密尔顿抑郁量表(21项)评分较基线降低≥50%的患者比例。
- 次要结局包括基线、方案期间(第4天、第19天、第26天)及方案结束时汉密尔顿抑郁量表和QIDS-SR-16评估的抑郁严重度变化。
- 次要结局还包括副作用(改编版UKU)、认知功能(记忆、注意力、视空间能力、主观认知抱怨)、自传体记忆(TEMPau)及电休克参数(癫痫特征和麻醉剂量)。
- 将使用多种磁共振成像序列(3D、静息态功能MRI、磁共振波谱)比较两组区域灰质密度、皮质厚度、脑连接及GABA水平的潜在变化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Major depressive disorder is a leading cause of disability worldwide, with treatment-resistant depression (TRD) affecting approximately one-third of patients and leading to increased morbidity and healthcare costs. Electroconvulsive therapy (ECT) remains a key treatment for TRD, but its efficacy is limited, and it is associated with cognitive side effects and delayed symptom relief. Repetitive transcranial magnetic stimulation (rTMS) shares action mechanisms with ECT and has shown potential in enhancing ECT efficacy in a previous trial. The STIMAGNECT 2 trial aims to evaluate whether an rTMS add-on protocol can improve ECT outcomes in TRD patients after 10 ECT sessions. METHODS: Eighty patients with TRD will be enrolled in a prospective multicentric double-blind randomized controlled trial. All patients will receive a total of 10 ECT sessions. Patients will be randomly assigned to an active or sham rTMS arm. The rTMS protocol (either active or sham) consists of 5 rTMS sessions over 4 days before the beginning of the ECT protocol, with an additional rTMS session the day before each ECT session from the 6th ECT session onward. The main outcome is the response rate following 10 ECT sessions, defined as the proportion of patients achieving a ≥ 50% reduction in their Hamilton Depression Rating Scale (HAMD, 21 items). Secondary outcomes include changes in depression severity (HAMD and QIDS-SR-16) at baseline, during the protocol (Day 4, Day 19, Day 26) and at the end of the protocol, as well as assessment of side effects (adapted UKU), cognitive function (memory, attention, visuospatial abilities, subjective cognitive complaint), autobiographical memory (TEMPau), and ECT session parameters such as seizure characteristics and anesthetic doses. Additionally, potential changes in regional gray matter density, cortical thickness, brain connectivity, and GABA levels will be compared between groups using several magnetic resonance imaging (MRI) sequences (3D, resting-state functional MRI, magnetic resonance spectroscopy). DISCUSSION: The aim of this trial is to optimize neurostimulation protocols using the synergistic effects of rTMS and ECT in order to improve the treatment of TRD. TRIAL REGISTRATION: ClinicalTrials.gov NCT06391723 Id RCB: 2023-A01813-42. The trial was registered on January 30, 2024.
引用
- Clabeau L, Moulier V, Kaczmarek B, et al. A prospective multicentre double-blind randomized controlled trial evaluating clinical, cognitive and neural effects of potentiation of electroconvulsive therapy by repetitive transcranial magnetic stimulation in patients with treatment-resistant depression (STIMAGNECT 2). Trials. 2026. PMID: 41582128. doi:10.1186/s13063-025-09406-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。